The evolution of therapeutic modalities drives the adoption of single-use technologies.

Review of SUT Adoption in Biopharma Manufacturing

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

 Automating the Future of Fill/Finish

Topic

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

Automating the Future of Fill/Finish

Cheryl Barton is director of PharmaVision, 

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

The partnership will allow for both companies to provide end-to-end biopharmaceutical manufacturing solutions.

BioCina and NovaCina to Partner on Drug Substance and Product Solutions for Biologics

Feliza Mirasol is the science editor for 

CordenPharma’s new starter kits are designed to enable effective formulation in the development of mRNA-based therapeutics.

CordenPharma Launches New LNP Starter Kits for mRNA Formulation

Videos

This discussion explores how the management and analysis of vast data generated by advanced analytical technologies are revolutionizing the drug discovery and development process within the biopharma industry.

Drug Digest: The Rush for Quality Data and the Means to Protect It

Webcasts

Webinar Date/Time: Tue, Apr 9, 2024 2:00 PM EDT




Leveraging the Power of Recipe-Driven Execution and Standardization

CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen. 

CSL Licenses Cytegrity Lentiviral Vector Production System to Genezen

Cameron Graham is senior process engineer, Biologics at BIOVECTRA.

Gregor Awang is specialist, Biologics Development and Innovation at BIOVECTRA.

Challenges in fermentation can be addressed through equipment changes, facility design, and process development.

High-Growth Microbial Fermentation for the Manufacture of Biologics

FDA has approved Iovance Biotherapeutics’ Amtagvi (lifileucel) for treating patients with unresectable or metastatic melanoma.

FDA Approves Amtagvi, First Cell Therapy for Skin Cancer

Webinar Date/Time: Thu, Mar 14, 2024 2:00 PM EDT


